{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:47:00Z","timestamp":1791316020223,"version":"4.3.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T00:00:00Z","timestamp":1350950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T00:00:00Z","timestamp":1350950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/tpj.2012.44","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T10:03:19Z","timestamp":1350986599000},"page":"498-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"13","author":[{"given":"E","family":"Lopez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Martin-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Garcia-Orad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,23]]},"reference":[{"key":"BFtpj201244_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2009.07898.x","volume":"148","author":"IJ Koppen","year":"2010","unstructured":"Koppen IJ, Hermans FJ, Kaspers GJ . Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol 2010; 148: 3\u201314.","journal-title":"Br J Haematol"},{"key":"BFtpj201244_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.canep.2010.06.020","volume":"34","author":"WT Johnston","year":"2010","unstructured":"Johnston WT, Lightfoot TJ, Simpson J, Roman E . Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol 2010; 34: 659\u2013666.","journal-title":"Cancer Epidemiol"},{"key":"BFtpj201244_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT . Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030\u20131043.","journal-title":"Lancet"},{"key":"BFtpj201244_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10038-006-0096-z","volume":"52","author":"H Imanishi","year":"2007","unstructured":"Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52: 166\u2013171.","journal-title":"J Hum Genet"},{"key":"BFtpj201244_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJM199610033351408","volume":"335","author":"R Gorlick","year":"1996","unstructured":"Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR . Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335: 1041\u20131048.","journal-title":"N Engl J Med"},{"key":"BFtpj201244_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1517\/14622416.5.7.819","volume":"5","author":"M Krajinovic","year":"2004","unstructured":"Krajinovic M, Moghrabi A . Pharmacogenetics of methotrexate. Pharmacogenomics 2004; 5: 819\u2013834.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201244_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ejca.2005.09.017","volume":"42","author":"K Swerts","year":"2006","unstructured":"Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philipp\u00e9 J . Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006; 42: 295\u2013309.","journal-title":"Eur J Cancer"},{"key":"BFtpj201244_CR8","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","volume":"27","author":"LR Trevi\u00f1o","year":"2009","unstructured":"Trevi\u00f1o LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27: 5972\u20135978.","journal-title":"J Clin Oncol"},{"key":"BFtpj201244_CR9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1053\/gast.2001.24804","volume":"120","author":"T Abe","year":"2001","unstructured":"Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120: 1689\u20131699.","journal-title":"Gastroenterology"},{"key":"BFtpj201244_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.ejca.2008.12.004","volume":"45","author":"E De Mattia","year":"2009","unstructured":"De Mattia E, Toffoli G . C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45: 1333\u20131351.","journal-title":"Eur J Cancer"},{"key":"BFtpj201244_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrc1800","volume":"6","author":"MH Cheok","year":"2006","unstructured":"Cheok MH, Evans WE . Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117\u2013129.","journal-title":"Nat Rev Cancer"},{"key":"BFtpj201244_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"P Frosst","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111\u2013113.","journal-title":"Nat Genet"},{"key":"BFtpj201244_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0021-9150(00)00671-7","volume":"156","author":"IS Weisberg","year":"2001","unstructured":"Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R et al. The 1298A\u2014>C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409\u2013415.","journal-title":"Atherosclerosis"},{"key":"BFtpj201244_CR14","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/leu.2008.66","volume":"22","author":"L Huang","year":"2008","unstructured":"Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R . Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 1798\u20131800.","journal-title":"Leukemia"},{"key":"BFtpj201244_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pi\u00f1an MA, Garcia-Miguel P, Navajas A et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57: 612\u2013619.","journal-title":"Pediatr Blood Cancer"},{"key":"BFtpj201244_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/10428190902893819","volume":"50","author":"M Kantar","year":"2009","unstructured":"Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 912\u2013917.","journal-title":"Leuk Lymphoma"},{"key":"BFtpj201244_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3109\/10428194.2011.563883","volume":"52","author":"SG Liu","year":"2011","unstructured":"Liu SG, Li ZG, Cui L, Gao C, Li WJ, Zhao XX . Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma 2011; 52: 1030\u20131040.","journal-title":"Leuk Lymphoma"},{"key":"BFtpj201244_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.mph.0000198269.61948.90","volume":"28","author":"N Shimasaki","year":"2006","unstructured":"Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006; 28: 64\u201368.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFtpj201244_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/gtmb.2010.0083","volume":"15","author":"NV Karathanasis","year":"2011","unstructured":"Karathanasis NV, Stiakaki E, Goulielmos GN, Kalmanti M . The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers 2011; 15: 5\u201310.","journal-title":"Genet Test Mol Biomarkers"},{"key":"BFtpj201244_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00277-007-0274-x","volume":"86","author":"S Pakakasama","year":"2007","unstructured":"Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Udomsubpayakul U, Sirachainan N, Thithapandha A et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 2007; 86: 609\u2013611.","journal-title":"Ann Hematol"},{"key":"BFtpj201244_CR21","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/0008-5472.CAN-04-2606","volume":"65","author":"R Aplenc","year":"2005","unstructured":"Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482\u20132487.","journal-title":"Cancer Res"},{"key":"BFtpj201244_CR22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3109\/10428194.2011.639880","volume":"53","author":"N Er\u010dulj","year":"2012","unstructured":"Er\u010dulj N, Kotnik BF, Debeljak M, Jazbec J, Dol\u017ean V . Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 1096\u20131104.","journal-title":"Leuk Lymphoma"},{"key":"BFtpj201244_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"B Faganel Kotnik","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dol\u017ean V, Jazbec J . Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67: 993\u20131006.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201244_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3109\/10428191003611402","volume":"51","author":"B Faganel Kotnik","year":"2010","unstructured":"Faganel Kotnik B, Dolzan V, Grabnar I, Jazbec J . Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2010; 51: 724\u2013726.","journal-title":"Leuk Lymphoma"},{"key":"BFtpj201244_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/tpj.2011.25","volume":"12","author":"J Salazar","year":"2011","unstructured":"Salazar J, Alt\u00e9s A, Del R\u00edo E, Estella J, Rives S, Tasso M et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J 2011; 12: 379\u2013385.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201244_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MBC.0b013e32833135e9","volume":"21","author":"AA Tantawy","year":"2010","unstructured":"Tantawy AA, El-Bostany EA, Adly AA, Abou El Asrar M, El-Ghouroury EA, Abdulghaffar EE . Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2010; 21: 28\u201334.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"BFtpj201244_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/08880011003739422","volume":"27","author":"M Horinouchi","year":"2010","unstructured":"Horinouchi M, Yagi M, Imanishi H, Mori T, Yanai T, Hayakawa A et al. Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol 2010; 27: 344\u2013354.","journal-title":"Pediatr Hematol Oncol"},{"key":"BFtpj201244_CR28","first-page":"1113","volume":"91","author":"I Costea","year":"2006","unstructured":"Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M . Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006; 91: 1113\u20131116.","journal-title":"Haematologica"},{"key":"BFtpj201244_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/pbc.20574","volume":"47","author":"K Chatzidakis","year":"2006","unstructured":"Chatzidakis K, Goulas A, Athanassiadou-Piperopoulou F, Fidani L, Koliouskas D, Mirtsou V . Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients. Pediatr Blood Cancer 2006; 47: 147\u2013151.","journal-title":"Pediatr Blood Cancer"},{"key":"BFtpj201244_CR30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0609.2008.01128.x","volume":"81","author":"PB van Kooten Niekerk","year":"2008","unstructured":"van Kooten Niekerk PB, Schmiegelow K, Schroeder H . Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol 2008; 81: 391\u2013398.","journal-title":"Eur J Haematol"},{"key":"BFtpj201244_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/pbc.23192","volume":"58","author":"DM Sepe","year":"2012","unstructured":"Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M et al. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer 2012; 58: 695\u2013700.","journal-title":"Pediatr Blood Cancer"},{"key":"BFtpj201244_CR32","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s12032-011-9997-6","volume":"29","author":"NM El-Khodary","year":"2011","unstructured":"El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN . Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2011; 29: 2053\u20132062.","journal-title":"Med Oncol"},{"key":"BFtpj201244_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.tpj.6500224","volume":"4","author":"M Krajinovic","year":"2004","unstructured":"Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A . Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4: 66\u201372.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201244_CR34","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","volume":"109","author":"S Kishi","year":"2007","unstructured":"Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151\u20134157.","journal-title":"Blood"},{"key":"BFtpj201244_CR35","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-011-1665-1","volume":"68","author":"V D'Angelo","year":"2011","unstructured":"D'Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011; 68: 1339\u20131346.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFtpj201244_CR36","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2003.07.056","volume":"21","author":"S Kishi","year":"2003","unstructured":"Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084\u20133091.","journal-title":"J Clin Oncol"},{"key":"BFtpj201244_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MPH.0b013e318165b25d","volume":"30","author":"N Shimasaki","year":"2008","unstructured":"Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008; 30: 347\u2013352.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFtpj201244_CR38","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00280-011-1719-4","volume":"68","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Ballesteros J, Garcia-Orad A . MTHFR 677TT genotype and toxicity of methotrexate: controversial results. Cancer Chemother Pharmacol 2011; 68: 1369\u20131370, author reply 1371.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201244","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T16:53:45Z","timestamp":1714496025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,23]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFtpj201244"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2012.44","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,23]]},"assertion":[{"value":"17 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}